Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering
NEWTOWN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech...
Brain
Odyssey Health, Inc. Launches New Corporate Website
Odyssey Health, Inc. Launches New Corporate Website $ODYY - Odyssey Health, Inc. - New Corporate WebsiteLas Vegas, NV, Aug. 04,...
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Healthy Extracts to Launch on Fullscript, the Leading Integrative Medicine Platform for 70,000 Healthcare Providers and 5 Million Patients
BergaMet PRO+ Citrus Bergamot SuperFruit™ BergaMet PRO+ Citrus Bergamot SuperFruit™LAS VEGAS, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc....
Best CBD Products By Exhale Wellness: Buy Oils, Gummies & Vapes (A Complete Guide)
GLENDALE, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- The farm bill of 2018 legalized the use of CBD with less...
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...
180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp.
PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled...
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Healthy Extracts Launches New Clinical Study Investigating UBN ACTIVATE™ Effect on Golfers’ Energy, Focus and Scores
Golf Performance Study Golfer undergoing V02 max profile to establish their basic aerobic fitness. ACTUAL EEG BRAIN SCAN BEFORE &...
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate...
Orphalan announces enrolment of the first five patients in the International Wilson’s Disease Patient Registry (“iWD Registry”)
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global...
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
Renowned neuroscience leader to further long-term clinical research strategy and external collaborationsCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion...
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint
•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest therapeutic...
Neuronetics and Alleviant Health Centers Announce Exclusive Partnership
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE...
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer’s Disease
Alzheimer's Association International Conference ("AAIC") – Systems Biology of Alzheimer's Disease Panel on August 4, 2022 Moderated by Jeffrey Cummings,...